Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01789281
Title Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Everolimus + Octreotide acetate

Age Groups: adult
Covered Countries USA | ITA | ESP

Facility Status City State Zip Country Details
Hematology Oncology Services of Arkansas SC Little Rock Arkansas 72205 United States Details
Rocky Mountain Cancer Centers SC Greenwood Village Colorado United States Details
Stamford Hospital Stamford Connecticut 06902 United States Details
H Lee Moffitt Cancer Center and Research Institute SC-2 Tampa Florida 33612 United States Details
Central Indiana Cancer Centers SC Indianapolis Indiana 46227 United States Details
Crescent City Research Consortium, LLC SC-3 Metairie Louisiana 70006 United States Details
Mayo Clinic SC-2 Rochester Minnesota 55905 United States Details
Washington University School of Medicine Dept of Oncology Saint Louis Missouri 63110 United States Details
Nebraska Cancer Specialists Onc Dept Omaha Nebraska 68154 United States Details
Clinical Research Alliance Lake Success New York 11042 United States Details
New York University Medical Center SC-4 New York New York 10016 United States Details
Oregon Health and Science University SC-8 Portland Oregon 97239 United States Details
Utah Cancer Specialists Utah Cancer (2) Salt Lake City Utah 84106 United States Details
Novartis Investigative Site Praha 2 Czech Republic 120 00 Czechia Details
Novartis Investigative Site Arezzo AR 52100 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 03722 Korea, Republic of Details
Novartis Investigative Site Groningen 9713 GZ Netherlands Details
Novartis Investigative Site Leningrad Region Russia 188663 Russian Federation Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Bangkok 10700 Thailand Details
Novartis Investigative Site Izmir 35040 Turkey Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field